

116

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: RTSP-0204
Inventors: Monia and Cowsert
Serial No.: 10/009,624
Filing Date: December 11, 2001
Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Title: Antisense Inhibition of JUN N-Terminal Kinase Kinase-2 Expression

I, Kathleen A. Tyrrell, Registration No. 38,350, certify that this correspondence is being depositing with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents and Trademarks, Washington, D.C. 20231.

On this date: April 9, 2002


Kathleen A. Tyrrell, Registration No. 38,350

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into

the national stage of the above identified application as set forth in \$1.491; or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311, therefore:
- () Certification in Accordance with \$1.97(e) is set forth below; or
- () The fee of \$180.00 as set forth in \$1.17(p) is attached.
- () In accordance with \$1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with \$1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in \$1.17(i)(1).
- () Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.
- (**XX**) In accordance with \$1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously


submitted to the U.S. Patent and Trademark Office in prior application Serial No. 09/344,001, filed June 24, 1999, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application or were previously submitted to the U.S. Patent and Trademark Office as the PCT Receiving Office and are referenced in the International Search Report (AL and AM).

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

~~(XX)~~ All listed references are in the English language.

Respectfully submitted,


Kathleen A. Tyrrell
Registration No. 38,350

Date: April 9, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified		Docket No. RTSP-0204	Serial No. 10/009,624
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Brett P. Monia et al.	
		Filing Date December 11, 2001	Group Not Yet Assigned
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Butterfield et al., Stress- and cell type-dependent regulation of transfected c-Jun N- terminal kinase and mitogen-activated protein kinase isoforms, <i>Biochem. J.</i> , 1999, 338:681-686	
	AB	Cuenda et al., Differential activation of stress-activated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogen-activated protein kinase kinase (MKK) kinase-1, <i>Biochem. J.</i> , 1998, 333:11-15	
	AC	Foltz et al., Human mitogen-activated protein kinase kinase 7 (MKK7) is a highly conserved c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) activated by environmental stresses and physiological stimuli, <i>J. Biol. Chem.</i> , 1998, 273:9344-9351	
	AD	Hirai et al., Differential activation of two JNK activators, MKK7 and SEK1, by MKK28- derived nonreceptor serine/threonine kinase/mixed lineage kinase 2, <i>J. Biol. Chem.</i> , 1998, 273:7406-7412	
	AE	Lu et al., Identification of c-Jun NH2-terminal protein kinase (JNK)-activating kinase 2 as an activator of JNK but not p38, <i>J. Biol. Chem.</i> , 1997, 272:24751-24754	
	AF	Matsuda et al., T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A, <i>J. Biol. Chem.</i> , 1998, 273:12378-12382	
	AG	Tournier et al., The MKK7 gene encodes a group of c-Jun NH2-terminal kinase kinases, <i>Mol. Cell. Biol.</i> , 1999, 19:1569-1581	
	AH	Toyoshima et al., Fas induces cytoplasmic apoptotic responses and activation of the MKK7- JNK/SAPK and MKK6-p38 pathways independent of CPP32-like proteases, <i>J. Cell. Biol.</i> , 1997, 139:1005-1015	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. RTSP-0204	Serial No. 10/009,624
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Brett P. Monia et al.	
		Filing Date December 11, 2001	Group Not Yet Assigned
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AI	Wu et al., "Molecular cloning and characterization of human JNKK2, a novel Jun NH2-terminal kinase-specific kinase", <i>Mol. Cell. Biol.</i> 1977 17:7407-7416	
	AJ	Yamauchi et al., "Differential regulation of mitogen-activated protein kinase kinase 4 (MKK4) and 7 (MKK7) by signaling from G protein beta gamma subunit in human embryonal kidney 293 cells", <i>J. Biol. Chem.</i> 1999 274:1957-1965	
	AK	Yang et al., "Molecular cloning and characterization of a human protein kinase that specifically activates c-Jun N-terminal kinase", <i>Gene</i> 1998 212:95-102	
	AL	James W., "Towards gene-inhibition therapy: a review of progress and prospects in the field of antiviral antisense nucleic acids and ribozymes", <i>Antiviral Chemistry & Chemotl.</i> 1991 2(4):191-214	
	AM	Milner et al., "Selecting effective antisense reagents on combinatorial oligonucleotide arrays", <i>Nature Biotechnology</i> 1997 15:537-541	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified		Docket No. RTSP-0204	Serial No. 10/009,624
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant Brett P. Monia et al.	
U.S. Department of Commerce Patent and Trademark Office		Filing Date December 11, 2001	Group Not Yet Assigned
U.S. PATENT DOCUMENTS			

Examiner's Initial		Document No.	Date	Name	Class	Subclass
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

FOREIGN PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Country	Translation YES NO	
	AO	WO 99/02547	01/21/1999	PCT	X	
	AP	WO 98/54203	12/03/1998	PCT	X	
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					
	AW					
	AX					
EXAMINER				DATE CONSIDERED		